Nowak C, Arnold W, Henneberger G, Tanneberger S
Arch Geschwulstforsch. 1980;50(8):747-57.
The antineoplastic effectivity of VCMF was compared with the combined therapy CRM plus DBD in the mouse tumor systems L1210, 1142 A and Lewis lung carcinoma. Therapy of tumor-bearing mice was carried out by administering doses on the basis of LD 10 or with doses directly calculated from the clinical study CMEA 0102. In the most of all experiments VCMF was superior to the combination CRM plus DBD.
在小鼠肿瘤系统L1210、1142 A和Lewis肺癌中,将VCMF的抗肿瘤有效性与联合疗法CRM加DBD进行了比较。对荷瘤小鼠的治疗是基于LD 10给药或使用从临床研究CMEA 0102直接计算出的剂量。在大多数实验中,VCMF优于CRM加DBD的联合疗法。